HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use ONDANSETRON safely and effectively. See full prescribing information for ONDANSETRON.
ONDANSETRON injection, for intravenous or intramuscular use
Initial U.S. Approval: 1991
RECENT MAJOR CHANGES
INDICATIONS AND USAGE
DOSAGE AND ADMINISTRATION
Prevention of Nausea and Vomiting Associated With Initial and Repeat Courses of Emetogenic Cancer Chemotherapy (2.1):
Prevention of Postoperative Nausea and/or Vomiting (2.2):
Patients With Severe Hepatic Impairment (2.3):
DOSAGE FORMS AND STRENGTHS
Injection: 2 mL single-dose vial and 20 mL multiple-dose vial. (3)
WARNINGS AND PRECAUTIONS
Chemotherapy-Induced Nausea and Vomiting:
Postoperative Nausea and/or Vomiting:
To report SUSPECTED ADVERSE REACTIONS, contact Hospira, Inc. at 1-800-441-4100 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
See 17 for PATIENT COUNSELING INFORMATION.
If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.